John M. L. Ebos

Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization.

A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Peering into the aftermath: The inhospitable host?

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.